New white paper details key technical milestones and validation of the company’s proprietary, capsule-based platform to accelerate breakthroughs across human health
BOSTON, Jan. 7, 2026 /PRNewswire/ — Somite, an AI-native TechBio company building the first universal virtual cell-signaling model, today announced its new identity, Cellular Intelligence. This rebrand reflects the company’s vision to understand, predict and control cell behavior. To mark the launch, the company released a white paper, Engineering Cell Fate: Towards a Foundation Model for Virtual Cell Signaling, detailing its approach to achieving that vision.
“Cells respond to signals in intricate ways that govern both health and disease, but we still do not understand the rules that determine these outcomes,” said Micha Breakstone, Ph.D., Co-Founder and CEO of Cellular Intelligence. “While the industry races to map the static geography of cells, we are building the navigation system to guide them. That is the shift our new name represents. By decoding the grammar of cell signaling, we are replacing trial and error with predictive engineering, allowing us to design regenerative therapies and model diseases with the precision of a true engineering discipline. We are building a future where biology is no longer destiny, but design.”
Scientific Co-Founder Olivier Pourquié, Ph.D., a tenured professor on leave from Harvard Medical School to serve as Chief Biology Officer and Head of Research at Cellular Intelligence, describes the engine behind this vision:
“Cellular Intelligence has built a proprietary capsule platform that enables cell-signaling analysis and data generation at scale, with 1,000x higher efficiency than existing methods. This enables us to test millions of signal combinations on differentiating pluripotent stem cells in parallel. This scale allows us to identify precise conditions needed to control cell differentiation and understand diseases, ultimately transforming the future of medicine.”
Engineering Cell Fate: Towards a Foundation Model for Virtual Cell Signaling
The newly released white paper outlines Cellular Intelligence’s solution to the challenge of predicting and controlling cellular behavior with the development of the first universal virtual cell-signaling model. It details how, in less than two years, the company progressed from concept to demonstrating in vitro and in silico proof-of-concept results. The white paper also outlines the company’s roadmap for the future, and highlights the applications and impact on the field, and ultimately on patient lives.
Key technical milestones highlighted in the report include:
Arjun Raj, Ph.D., a tenured professor on leave from the University of Pennsylvania to serve as Head of Computational Biology, details the impact of this data engine:
“We have successfully executed some of the largest combinatorial signaling experiments the field has seen, demonstrating the ability to scale to over 1 million unique combinations, and we have already proven that our platform can generate a diverse set of cell types within a single run. This leaves us at a critical inflection point: our data engine is operating at the scale required to unlock the power of machine learning techniques, with massive, high-fidelity datasets yielding more powerful and generalizable models than ever before. These advances stand to transform research and development.”
To learn more about Cellular Intelligence and read the white paper, visit www.CellularIntelligence.com.
About Cellular Intelligence
Cellular Intelligence is an AI-native TechBio company building the first universal virtual cell-signaling model to decode and control the language of cells. Using our proprietary capsule technology, we generate dynamic cellular data at over 1,000x higher efficiency than existing methods. We train large-scale predictive models on this data to transform biology into an engineering discipline, enabling us to design and optimize regenerative medicine protocols, predict drug responses, and computationally model disease mechanisms. Our founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of MIT’s Fundamental AI Group, and four world-renowned professors, including three Harvard Medical School professors, three members of the National Academy of Sciences or Medicine, and the Chair of Genetics at Harvard Medical School. Based in Boston, Cellular Intelligence has raised over $62M to date from Khosla Ventures, the Chan Zuckerberg Initiative, SciFi VC, AMD Ventures, Fusion Fund, and others. Learn more at www.CellularIntelligence.com.
Contact: Media-Relations@CellularIntelligence.com
SOURCE Cellular Intelligence
Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…